公司資料
Biofrontera Inc 股價、新聞與催化劑
- 股票代碼:
- BFRI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.35 USD (+3.85%)
收盤價
最後更新: 2026年8月17日
13.2M USD
市值
股價為何變動
As of Aug 17, 2026, BFRI closed up 3.85% at $1.35. No new same-company headline was identified in the current news window.
公司概覽
Dermatology Photodynamic Therapy
Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system.
Actinic Keratosis Franchise
Ameluz is established in actinic keratosis and is being developed for broader treatment fields and additional body locations. The company is also pursuing superficial basal cell carcinoma and acne to expand the platform.
U.S. Commercial Infrastructure
Biofrontera operates a specialist dermatology sales organization and has restructured its economics with Biofrontera AG to retain a larger share of product value.
未來催化劑
- FDA action on the Ameluz supplemental application for superficial basal-cell carcinoma in late September 2026.
- Potential U.S. launch of Ameluz in superficial basal-cell carcinoma in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。